Assessment of Oxygen Saturation in Breast Lesions Using Photoacoustic Imaging: Correlation With Benign and Malignant Disease.

BACKGROUND

Hypoxia is a hallmark of breast cancer (BC). Photoacoustic (PA) imaging, based on the use of laser-generated ultrasound (US), can detect oxygen saturation (So) in the tissues of breast lesion patients.

PURPOSE

To measure the oxygenation status of tissue in and on both sides of the lesion in breast lesion participants using a multimodal Photoacoustic/ultrasound (PA/US) imaging system and to determine the correlation between So measured by PA imaging and benign or malignant disease.

MATERIALS AND METHODS

Multimodal PA/US imaging and gray-scale US (GSUS) of breast lesion was performed in consecutive breast lesion participants imaged in the US Outpatient Clinic between 2022 and 2023. Dual-wavelength PA imaging was used to measure the So value inside the lesion and on both sides of the tissue, and to distinguish benign from malignant lesions based on the So value. The ability of So to distinguish benign from malignant breast lesions was evaluated by the receiver operating characteristic curve (ROC) and the De-Long test.

RESULTS

A total of 120 breast lesion participants (median age, 42.5 years) were included in the study. The malignant lesions exhibited lower So levels compared to benign lesions (malignant: 71.30%; benign: 83.81%; P < .01). Moreover, PA/US imaging demonstrates superior diagnostic results compared to GSUS, with an area under the curve (AUC) of 0.89 versus 0.70, sensitivity of 89.58% versus 85.42%, and specificity of 86.11% versus 55.56% at the So cut-off value of 78.85 (P < .001). The false positive rate in GSUS reduced by 30.75%, and the false negative rate diminished by 4.16% with PA /US diagnosis. Finally, the So on both sides tissues of malignant lesions are lower than that of benign lesions (P < .01).

CONCLUSION

PA imaging allows for the assessment of So within the lesions of breast lesion patients, thereby facilitating a superior distinction between benign and malignant lesions.